Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
We also applied CTM to construct a novel ECL immunosensor and achieve the sensitive detection of the proprotein convertase subtilisin/kexin type 9 (PCSK9), a biomarker related to cardiovascular diseases (CVDs).
|
31794188 |
2020 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases.
|
31419281 |
2020 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease.
|
30786741 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
A published Markov model was adopted to investigate lifetime outcomes: (1) number of recurrent CVD events prevented, (2) quality-adjusted life-years (QALYs) gained, (3) costs and (4) incremental cost-effectiveness ratios (ICERs) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe added to statin therapy.
|
31243736 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Our systematic review included randomised controlled trials if they studied PCSK9 inhibitors in patients for primary and/or secondary prevention of cardiovascular diseases or with hypercholesterolaemia/hyperlipidaemia.
|
30842207 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
High PCSK9 concentrations are associated with an increased risk of cardiovascular disease (CVD).
|
31002780 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
|
31832834 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
There is no available evidence on the efficacy and safety of PCSK9 inhibitors in non-cardiovascular diseases, particularly cancer.
|
31110520 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels.
|
29103916 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
LDL cholesterol (LDL-C) lowering drugs that operate through the inhibition of PCSK9 are being pursued for the management of hypercholesterolemia and reducing its associated atherosclerotic cardiovascular disease (CVD) risk.
|
30448414 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Hence, design an effective method to detect serum PCSK9 is meaningful for the prevention, monitor and diagnosis of cardiovascular diseases.
|
31513960 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
LDLR and PCSK9 polymorphisms have been associated with higher lipid levels and risk of cardiovascular diseases.
|
31441123 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Here we review the history of PCSK9 and rationale behind developing inhibitors for CVD.
|
30914377 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to date, no randomized controlled trial has demonstrated that lowering of lipoprotein(a) leads to lower risk of cardiovascular disease.
|
31111240 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes.
|
30551367 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although PCSK9 inhibitors were shown to reduce the risk of cardiovascular disease, a warning was issued concerning their possible impact on cognitive functions.
|
31437157 |
2019 |
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PCSK9 inhibitors potently lower plasma LDL-C levels in T2DM patients and reduce risk for the development of cardiovascular disease.
|
31002456 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
PCSK9 regulates LDL receptor degradation and plays key roles in hypercholesterolemia and related cardiovascular diseases.
|
31593224 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study.
|
30709868 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5-10% of high-risk cardiovascular patients reach the target values recommended by international guidelines.
|
31818446 |
2019 |
Cardiovascular Diseases
|
0.200 |
AlteredExpression
|
group |
BEFREE |
PCSK-9 levels were higher in statin users and patients with a history of cardiovascular disease.
|
30921469 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique.
|
29685715 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Characteristics associated with a higher CVD risk may inform the decision to initiate PCSK9 inhibition.
|
30746585 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
<i>Gold standard</i> therapy with statins and the more recently developed <i>proprotein convertase subtilisin/kexin type 9</i> (PCSK9) inhibitors have improved health conditions among CVD patients by lowering <i>low density lipoprotein</i> (LDL) cholesterol.
|
31191301 |
2019 |